Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines

Prostate

Volumn 72, Issue 13, 2012, Pages 1407-1411

  Ide, Hisamitsu ^a   Lu, Yan ^a   Yu, Jingsong ^a   China, Toshiyuki ^a   Kumamoto, Tomoka ^a   Koseki, Tatsuro ^a   Yamaguchi, Raizo ^a   Muto, Satoru ^a   Horie, Shigeo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

androgen receptor; DNA damage response; oxidative stress; prostate cancer; testosterone

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANDROGEN RECEPTOR; ATAXIA TELANGIECTASIA MUTATED KINASE; CHECKPOINT KINASE 2; FLUTAMIDE; HISTONE H2AX; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TESTOSTERONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL STRAIN LNCAP; DNA DAMAGE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA-BINDING PROTEINS; HISTONES; HUMANS; HYDROGEN PEROXIDE; MALE; OXIDATIVE STRESS; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TESTOSTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 84864869615     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22492     Document Type: Article

References (15)

1. Wiren S, Stattin P,. Androgens and prostate cancer risk. Best Pract Res Clin Endocrinol Metab 2008; 22 (4): 601-613.
2. Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, Komiya A, Nihei N, Naya Y, Ichikawa T,. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 2008; 15 (6): 472-480. (Pubitemid 351713199)
3. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI,. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56 (2): 237-244.
4. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM,. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56 (1): 97-103.
5. Malins DC, Johnson PM, Wheeler TM, Barker EA, Polissar NL, Vinson MA,. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res 2001; 61 (16): 6025-6028. (Pubitemid 32762532)
6. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, Anderson KM,. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003; 100 (9): 5401-5406. (Pubitemid 36542717)
7. Bartek J, Bartkova J, Lukas J,. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007; 26 (56): 7773-7779. (Pubitemid 350242463)
8. Jackson SP, Bartek J,. The DNA-damage response in human biology and disease. Nature 2009; 461 (7267): 1071-1078.
9. Fan C, Quan R, Feng X, Gillis A, He L, Matsumoto ED, Salama S, Cutz JC, Kapoor A, Tang D,. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta 2006; 1763 (10): 1090-1097. (Pubitemid 44466123)
10. Valavanidis A, Vlachogianni T, Fiotakis C,. 8-hydroxy-2' -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009; 27 (2): 120-139.
11. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224. (Pubitemid 36859473)
12. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R,. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172 (4 Pt 1): 1314-1317. (Pubitemid 39249705)
13. Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Horie S,. Development of a nomogram for predicting high-grade prostate cancer on biopsy: The significance of serum testosterone levels. Anticancer Res 2008; 28 (4C): 2487-2492.
14. Angele S, Falconer A, Edwards SM, Dork T, Bremer M, Moullan N, Chapot B, Muir K, Houlston R, Norman AR, Bullock S, Hope Q, Meitz J, Dearnaley D, Dowe A, Southgate C, Ardern-Jones A, Easton DF, Eeles RA, Hall J,. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004; 91 (4): 783-787. (Pubitemid 39141641)
15. Wu X, Dong X, Liu W, Chen J,. Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 2006; 27 (8): 742-747. (Pubitemid 44205067)